NCT02993068
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Early Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: Female
Age: 30 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: See trial for specific eligibility criteria
Exclusions: Patients with a personal history of ovarian cancer
https://ClinicalTrials.gov/show/NCT02993068